Let’s take a look at why Onconova Therapeutics, Inc. (ONTX) surged in the Postmarket hours
Onconova Therapeutics, Inc. (NASDAQ: ONTX), shares rose above 37% to 0.586 in the post-market session today after the news that it has earned the U.S. Food and Drug Administration (FDA) clearance for a Phase 1 analysis to continue with ON 123300, a proprietary, differentiated, first-in-class multi-kinase inhibitor, under the Company’s Investigational New Drug Application (IND). […]
